Advertisement
ANI Pharma Guides FY23 Adj. EPS Below Estimates, But Revenues Above - Update
(RTTNews) - While reporting financial results for the fourth quarter on Thursday, biopharmaceutical company ANI Pharmaceuticals, Inc. (ANIP) initiates adjusted earnings and net revenue guidance for the full-year 2023.
For fiscal 2023, the company now projects adjusted earnings in a range of $2.09 to $2.59 per share on net revenues between $360 million and $385 million, with purified cortrophin gel revenue at $80 million to $90 million.
On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.62 per share on revenues of $352.49 million for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
read more
ANI Pharma Launches Kionex Suspension For Oral Or Rectal Use
Biopharmaceutical company ANI Pharmaceuticals, Inc. (ANIP) announced Monday the launch of Kionex (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use.
RTTNews
|
338 days ago
ANI Pharma Says FDA Approves Methsuximide Capsules, Alendronate Sodium Oral Solution
ANI Pharmaceuticals, Inc. (ANIP) announced Monday that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Applications (ANDAs) for Methsuximide Capsules USP, 300 mg and Alendronate Sodium Oral Solution 70 mg (base)/75 mL.
RTTNews
|
709 days ago
ANI Pharmaceuticals Says FDA Oks ANDA For Clorazepate Dipotassium Tablets
ANI Pharmaceuticals, Inc. (ANIP) announced Wednesday that it has received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Clorazepate Dipotassium Tablets.
RTTNews
|
1036 days ago
Bay Street Likely To Open On Firm Note
Sharply higher U.S. and Canadian futures point to a firm start for the Canadian markets on Wednesday. Global stocks gained in strength today with investors reacting positively to U.S. President Donald Trump's softer tone toward Federal Reserve Chair Jerome Powell, and his admission that the 145% tariffs on China are "very high" and they will come down substantially.
RTTNews
|
53 minutes ago
FTSE 100 Notably Higher On Easing Tariff Concerns
The U.K. stock market remains firmly place in positive territory on Monday after a bright start as U.S. President Donald Trump has toned down his rhetoric on Jerome Powell, and also admitted that the 145% tariffs on China are "very high."
RTTNews
|
1h 32min ago
German Private Sector Falls Back Into Contraction
Germany's private sector fell into the contraction territory in April as trade tariff concerns damped business confidence and demand, flash purchasing managers' survey by S&P Global revealed Wednesday. The composite output index fell to 49.7 in April from 51.3 in March. The score fell below the 50.0 no-change mark for the first time in four months.
RTTNews
|
1h 57min ago
Tesla Stock Gains As Musk Plans DOGE Cutback, Despite Weak Q1
Shares of Tesla, Inc. were gaining around 7 percent in the pre-market hours on the Nasdaq, continuing an upbeat activity on Tuesday's after-hours, after CEO Elon Musk announced that he will reduce time with President Donald Trump's Department of Government Efficiency or DOGE significantly, starting in May. The announcement on the luxury electric vehicle maker's earnings call came after reporting..
RTTNews
|
2h 0min ago
CAC 40 Up Nearly 2.5% As Stocks Rally On Positive Global Cues
French stocks are up sharply on Wednesday with investors reacting to U.S. President Donald Trump's softer tone toward Federal Reserve Chair Jerome Powell, and his admission that the 145% tariffs on China are "very high" and they will come down substantially.
RTTNews
|
2h 9min ago
